Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics reported a 44% increase in its half-year loss to A$26.97 million for the six months ended 31 December 2025, with net tangible assets per share declining to 0.14 cents from 0.18 cents a year earlier. The company did not declare any dividends, while its interim financial statements received an unmodified review opinion from its independent auditor.
During the period, Radiopharm Theranostics increased its stake in Radiopharm Ventures, LLC, a joint venture with The University of Texas M.D. Anderson Cancer Center, from 75% to 87.5%. The higher ownership in this oncology-focused venture underscores the company’s strategic commitment to expanding its theranostic platform despite widening losses and the absence of shareholder distributions.
The most recent analyst rating on (AU:RAD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the medical and biotechnology sector, focusing on theranostics, which combine diagnostic imaging and targeted radiopharmaceutical therapies, particularly in oncology. The company develops and commercialises radiopharmaceutical products aimed at improving cancer detection and treatment outcomes in global healthcare markets.
Average Trading Volume: 10,146,395
Technical Sentiment Signal: Sell
Current Market Cap: A$77.97M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.